Cargando…
Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018
IMPORTANCE: Over the past decade, branded prescription drug manufacturers have substantially increased list prices while offering larger rebate payments to health care insurers. Whereas larger rebates can partially offset increases in list prices for insurers, patient out-of-pocket costs may be dire...
Autores principales: | Yeung, Kai, Dusetzina, Stacie B., Basu, Anirban |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204201/ https://www.ncbi.nlm.nih.gov/pubmed/34125219 http://dx.doi.org/10.1001/jamanetworkopen.2021.13393 |
Ejemplares similares
-
Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018
por: Lakdawalla, Darius, et al.
Publicado: (2021) -
Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018
por: Peet, Evan D., et al.
Publicado: (2022) -
Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019
por: Erath, Alexandra, et al.
Publicado: (2020) -
Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use
por: Auty, Samantha G., et al.
Publicado: (2021) -
Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs
por: Wong, William Bruce, et al.
Publicado: (2023)